Our conversations are with both developed-country and developing-country manufacturers. They've pointed to a series of problems and barriers. Intellectual property is not the one we're hearing about. It's more around issues such as export restrictions, access to inputs and having the technological know-how at the other end to actually assist in the manufacturing of the vaccines. This is what we are hearing at this point.
On April 30th, 2021. See this statement in context.